Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Cash & Current Investments (2017 - 2025)

Cue Biopharma (CUE) has disclosed Cash & Current Investments for 9 consecutive years, with $27.7 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments rose 18.41% to $27.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.7 million through Dec 2025, up 18.41% year-over-year, with the annual reading at $27.7 million for FY2025, 18.41% up from the prior year.
  • Cash & Current Investments hit $27.7 million in Q4 2025 for Cue Biopharma, up from $18.2 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $76.3 million in Q4 2022 to a low of $14.0 million in Q1 2025.
  • Historically, Cash & Current Investments has averaged $48.9 million across 5 years, with a median of $53.4 million in 2021.
  • Biggest five-year swings in Cash & Current Investments: soared 50.33% in 2021 and later plummeted 65.76% in 2025.
  • Year by year, Cash & Current Investments stood at $52.2 million in 2021, then skyrocketed by 46.12% to $76.3 million in 2022, then tumbled by 36.03% to $48.8 million in 2023, then tumbled by 52.07% to $23.4 million in 2024, then grew by 18.41% to $27.7 million in 2025.
  • Business Quant data shows Cash & Current Investments for CUE at $27.7 million in Q4 2025, $18.2 million in Q3 2025, and $28.0 million in Q2 2025.